###begin article-title 0
p27 Deficiency Cooperates with Bcl-2 but Not Bax to Promote T-Cell Lymphoma
###end article-title 0
###begin p 1
Conceived and designed the experiments: CK NC Cv. Performed the experiments: NC Cv. Analyzed the data: CK NC Cv. Wrote the paper: CK Cv.
###end p 1
###begin p 2
Current address: Department of Pathology, Medical College of Georgia, Augusta, Georgia, United States of America
###end p 2
###begin p 3
###xml 585 600 <span type="species:ncbi:10090">transgenic mice</span>
###xml 793 797 <span type="species:ncbi:10090">mice</span>
###xml 944 948 <span type="species:ncbi:10090">mice</span>
###xml 1032 1047 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1133 1137 <span type="species:ncbi:10090">mice</span>
###xml 1386 1390 <span type="species:ncbi:10090">mice</span>
The effect of Bcl-2 on oncogenesis is complex and expression may either delay or accelerate oncogenesis. The pro-oncogenic activity is attributed to its well characterized anti-apoptotic function while the anti-oncogenic function has been attributed to its inhibition of cellular proliferation. Recent studies demonstrate that p27 may mediate the effects of Bcl-2 on cellular proliferation. We hypothesized that p27 may suppress tumor formation by Bcl-2 family members. To test this hypothesis, cell cycle inhibition and lymphoma development were examined in Lck-Bcl-2 and Lck-Bax38/1 transgenic mice deficient in p27. Strikingly, p27 deficiency synergistically cooperates with Bcl-2 to increase T cell hyperplasia and development of spontaneous T cell lymphomas. Within 1 year, >90% of these mice had developed thymic T cell lymphomas. This high penetrance contrasts with a one year incidence of <5% of thymic lymphoma in Lck-Bcl-2 or p27 -/- mice alone. In contrast, p27 deficiency had no effect on tumor formation in Lck-Bax38/1 transgenic mice, another model of T cell lymphoma. Histologically the lymphomas in p27 -/- Lck-Bcl-2 mice are lymphoblastic and frequently involve multiple organs suggesting an aggressive phenotype. Interestingly, in mature splenic T cells, Bcl-2 largely retains its anti-proliferative function even in the absence of p27. T cells from p27 -/- Lck-Bcl-2 mice show delayed kinetics of CDK2 Thr-160 phosphorylation. This delay is associated with a delay in the up regulation of both Cyclin D2 and D3. These data demonstrate a complex relationship between the Bcl-2 family, cellular proliferation, and oncogenesis and demonstrate that p27 up-regulation is not singularly important in the proliferative delay observed in T cells expressing Bcl-2 family members. Nonetheless, the results indicate that p27 is a critical tumor suppressor in the context of Bcl-2 expression.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 112 115 112 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Cleary1">[1]</xref>
###xml 116 119 116 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Tsujimoto1">[3]</xref>
###xml 274 275 274 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 314 317 314 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Chao1">[4]</xref>
###xml 319 322 319 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Kuwana1">[5]</xref>
###xml 691 694 685 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Kuwana1">[5]</xref>
###xml 696 699 690 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Breckenridge1">[6]</xref>
###xml 826 829 820 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Harris1">[7]</xref>
###xml 1024 1027 1018 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-MacCarthyMorrogh1">[8]</xref>
###xml 78 83 <span type="species:ncbi:9606">human</span>
The Bcl-2 oncogene was discovered at the t(14;18) translocation breakpoint in human B cell follicular lymphomas [1]-[3]. Bcl-2 is a member of a large family of proteins that are critical regulators of cell death. This family is comprised of both anti-apoptotic (Bcl-2, Bcl-XL) and pro-apoptotic members (Bax, Bak) [4], [5]. Bcl-2 predominantly resides at the outer mitochondrial membrane and is able to block a number of mitochondrial changes that occur with apoptosis such as loss of mitochondrial membrane potential (DeltaPsim), release of mitochondrial proteins such as cytochrome C and Apoptosis-Inducing Factor (AIF), and opening of the mitochondrial permeability transition pore (PTP) [5], [6]. Bcl-2 also functions by preventing the formation of a complex that involves pro-apoptotic family members such as Bak and Bax [7]. Due to its anti-apoptotic function, Bcl-2 is thought to enhance oncogenesis by prolonging the survival of cells with pre-tumorigenic lesions and therefore increase the likelihood of malignancy [8].
###end p 5
###begin p 6
###xml 148 151 148 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Meterissian1">[9]</xref>
###xml 152 156 152 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Kaklamanis1">[13]</xref>
###xml 175 179 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Silvestrini1">[14]</xref>
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-delaCoste1">[15]</xref>
###xml 421 425 421 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Murphy1">[16]</xref>
###xml 479 483 479 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Rossiter1">[17]</xref>
###xml 623 627 623 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Luke1">[18]</xref>
###xml 629 633 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-vandeWetering1">[19]</xref>
###xml 129 134 <span type="species:ncbi:9606">human</span>
###xml 246 251 <span type="species:ncbi:10090">mouse</span>
###xml 592 607 <span type="species:ncbi:10090">transgenic mice</span>
Paradoxically, Bcl-2 expression is not always correlated with accelerated oncogenesis and a poor clinical outcome. In studies of human colon cancer [9]-[13] and breast cancer [14] increased Bcl-2 expression correlated with prolonged survival. In mouse models of cancer, Bcl-2 expression resulted in delayed tumor development in c-myc driven hepatocellular carcinoma [15], dimethylbenz(a)anthracene induced mammary tumors [16], and UV or chemical induced squamous cell carcinomas [17]. Moreover, we recently demonstrated that Bcl-2 suppressed lymphoma formation and chromosomal instability in transgenic mice expressing Bax [18], [19]. In many of these studies, the tumor-suppressive effect of Bcl-2 correlated with decreased cellular proliferation.
###end p 6
###begin p 7
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Marvel1">[20]</xref>
###xml 415 419 415 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Huang1">[21]</xref>
###xml 486 490 486 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Vairo1">[22]</xref>
###xml 813 821 813 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 821 825 821 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-OReilly1">[23]</xref>
###xml 826 830 826 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-OReilly3">[25]</xref>
###xml 988 992 988 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Linette1">[26]</xref>
###xml 1007 1014 1007 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1109 1113 1109 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Strasser1">[27]</xref>
###xml 750 765 <span type="species:ncbi:10090">transgenic mice</span>
###xml 908 912 <span type="species:ncbi:10090">mice</span>
###xml 1041 1056 <span type="species:ncbi:10090">transgenic mice</span>
A variety of studies have shown Bcl-2 has a significant anti-proliferative effect on different cell types. In BAF3 cells following IL-3 withdrawal, Bcl-2 expressing cells rapidly arrested in the G1 phase of the cell cycle and were refractory to re-stimulation when IL-3 was added back [20]. Moreover, in both fibroblasts and IL-3 dependent cells arrested in G0, Bcl-2 expression increased the time to reach S phase [21]. Bcl-2 was also shown to accelerate cell cycle withdrawal into G0 [22]. Together, these findings demonstrate that Bcl-2 regulates cellular proliferation by controlling the G0 to G1 transition. Several studies on the effect of Bcl-2 on resting lymphocytes are consistent with this interpretation. B-lymphocytes isolated from Bcl-2 transgenic mice were resistant to activation and proliferation in vitro[23]-[25]. Similarly, T cells isolated from Bcl-2 transgenic, wild-type, and deficient mice demonstrated an inverse correlation between Bcl-2 levels and proliferation [26]. Furthermore, in vivo, B-lymphocytes from Bcl-2 transgenic mice displayed delayed activation following immunization [27].
###end p 7
###begin p 8
###xml 378 382 378 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Huang1">[21]</xref>
###xml 651 655 651 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Janumyan1">[28]</xref>
###xml 657 661 657 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Cheng1">[29]</xref>
###xml 756 763 756 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 858 862 858 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Cheng1">[29]</xref>
###xml 473 488 <span type="species:ncbi:10090">transgenic mice</span>
An important point that remains controversial is whether the same or distinct functions of Bcl-2 account for the anti-proliferative and anti-apoptotic activities. In one study using cell lines, a single point mutation at tyrosine 28 (to Ala, Ser, and Phe) in the BH4 domain was able to ablate the anti-proliferative effect without affecting the anti-apoptotic function of Bcl-2 [21]. In contrast to this finding, other reports using this same mutation in cell lines and in transgenic mice demonstrated a tight correlation between the anti-apoptotic and anti-proliferative functions of Bcl-2 and demonstrated these two functions could not be separated [28], [29]. Alternatively, these reports suggest that cell cycle delay by Bcl-2 depends on the prolonged in vivo survival of these cells which results in reduced cell size and delayed cellular proliferation [29].
###end p 8
###begin p 9
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Janumyan1">[28]</xref>
###xml 174 178 174 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Vairo2">[30]</xref>
###xml 264 268 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Sherr1">[31]</xref>
###xml 374 378 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Sherr1">[31]</xref>
###xml 545 549 545 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Vairo2">[30]</xref>
###xml 663 667 <span type="species:ncbi:10090">mice</span>
In multiple reports, molecular analysis of Bcl-2-mediated inhibition of cell cycle has consistently shown that p27 protein levels are elevated in cells expressing Bcl-2 [28]-[30]. P27 is a Cyclin Dependent Kinase Inhibitor (CKI) and a member of the Cip/Kip family [31]. In particular, p27 has been suggested to act by inhibiting the activation of CDK2, a critical G1 kinase [31]. While the mechanism by which Bcl-2 elevates p27 levels is unknown, one study reported that Bcl-2 was unable to inhibit cellular proliferation in p27 deficient cells [30]. These studies prompted us to examine the role of p27 in both cell cycle control and malignant transformation in mice over-expressing Bcl-2.
###end p 9
###begin p 10
###xml 233 237 <span type="species:ncbi:10090">mice</span>
Here we report a striking synergistic cooperation between p27 deficiency and Bcl-2 in thymic lymphoma development. Despite this synergy, Bcl-2 largely retains its anti-proliferative function in p27 -/- deficient splenic T cells from mice prior to lymphoma development. These findings demonstrate a complex relationship between p27 and Bcl-2 with regards to cellular proliferation, and oncogenesis. The data show that up-regulation of p27 is not singularly important in the proliferative delay observed in T cells expressing Bcl-2. However, p27 functions as a critical tumor suppressor in the context of enforced Bcl-2 expression in thymocytes.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
###xml 40 44 <span type="species:ncbi:10090">mice</span>
T cell hyperplasia in p27 -/- Lck-Bcl-2 mice
###end title 12
###begin p 13
###xml 225 229 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Sentman1">[32]</xref>
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Knudson1">[33]</xref>
###xml 606 615 606 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g001">Figure 1A</xref>
###xml 675 684 675 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g001">Figure 1B</xref>
###xml 725 733 725 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 824 833 824 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g001">Figure 1C</xref>
###xml 1116 1125 1116 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g002">Figure 2A</xref>
###xml 1195 1199 1195 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Linette1">[26]</xref>
###xml 1251 1255 1251 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Cheng1">[29]</xref>
###xml 1459 1468 1459 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g002">Figure 2B</xref>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 421 425 <span type="species:ncbi:10090">mice</span>
###xml 933 937 <span type="species:ncbi:10090">mice</span>
###xml 1054 1058 <span type="species:ncbi:10090">mice</span>
###xml 1110 1114 <span type="species:ncbi:10090">mice</span>
To examine whether p27 functions as a critical suppressor of cell proliferation, lymphoid hyperplasia, and oncogenesis downstream of Bcl-2, p27 deficient mice were crossed to mice over-expressing Bcl-2 in T cells (Lck-Bcl-2) [32]. Lymphoid hyperplasia was assessed by determining the number of T cells (CD3 +) and B cells (B220 +) present in the spleen [33]. As expected from previous studies, both Lck-Bcl-2 and p27 -/- mice had modestly enlarged spleens and increased splenic T cells. However, the combination of Lck-Bcl-2 and p27 -/- deficiency proved synergistic as the spleens were markedly enlarged (Figure 1A) and the number of splenic T cells dramatically increased (Figure 1B). As expected, Bcl-2 markedly prolonged in vitro T cell survival while p27 expression had no effect on survival with or without Lck-Bcl-2 (Figure 1C). Staining of splenic B and T cells demonstrates no change in the percentage of T cells in p27 -/- mice versus the p27 +/- control. In contrast, Bcl-2 expression markedly increased the percentage of T cells with p27 -/- mice showing an even higher percentage than the p27 +/- mice (Figure 2A). Previous results had demonstrated that Bcl-2 decreases T cell size [26] which was correlated with inhibition of cell cycle [29]. We therefore examined whether the reduction in splenic T cell size as measured by forward scatter was dependent upon p27. Bcl-2 effectively decreased splenic T cell size in p27 +/- and p27 -/- strains (Figure 2B).
###end p 13
###begin title 14
###xml 42 46 <span type="species:ncbi:10090">mice</span>
Lymphoid hyperplasia in p27 -/- Lck-Bcl-2 mice.
###end title 14
###begin p 15
###xml 156 177 156 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 422 443 422 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 676 697 674 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 67 82 <span type="species:ncbi:10090">transgenic mice</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 477 481 <span type="species:ncbi:10090">mice</span>
###xml 597 601 <span type="species:ncbi:10090">mice</span>
###xml 747 752 <span type="species:ncbi:120290">Guava</span>
Spleens were dissected and T cells isolated from p27 -/- Lck-Bcl-2 transgenic mice and analyzed for viability and total splenic T cells as described in the Materials and Methods. Control groups included p27 -/-, p27 +/-, and p27 +/- Lck-Bcl-2 mice. A) Representative images of spleens from mice of the indicated genotypes. B) Total splenic T cells were determined by staining with an anti-CD3 antibody as described in the Materials and Methods. The Mean+/-SD of at least three mice is shown for the genotypes indicated. * P value <0.01 compared to all three other groups. C) Purified T cells from mice of the indicated genotypes were prepared and cultured as described in the Materials and Methods. Viability was determined over time by using the Guava Flow cytometer and Viacount reagent. The mean+/-SD for duplicate samples are shown.
###end p 15
###begin title 16
###xml 64 68 <span type="species:ncbi:10090">mice</span>
Splenic T cell hyperplasia and T cell size in p27 -/- Lck-Bcl-2 mice.
###end title 16
###begin p 17
###xml 153 174 153 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 501 522 501 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 552 556 <span type="species:ncbi:10090">mice</span>
###xml 640 644 <span type="species:ncbi:10090">mice</span>
###xml 703 707 <span type="species:ncbi:10090">mice</span>
###xml 768 772 <span type="species:ncbi:10090">mice</span>
A) Total splenic cells from mice of the indicated genotypes were isolated and stained with anti-B220-PE and anti-CD3-FITC antibodies as described in the Materials and Methods. The percentage of CD3-positive cells and the total number of splenic T cells (total # of splenic cells X %CD3) is shown. The data are representative of at least three mice from each genotype. B) The Mean Forward Scatter of CD3 positive splenic T cells was determined by staining with an anti-CD3 antibody as described in the Materials and Methods. The Mean+/-SD of at least 5 mice is shown for the genotypes indicated. * P<0.01 versus both the p27 +/- and p27 -/- mice using the unpaired Students T test. The p27 +/- Lck-Bcl-2 mice were not significantly different than the P27 -/- Lck-Bcl-2 mice (P = 0.89).
###end p 17
###begin title 18
###xml 63 67 <span type="species:ncbi:10090">mice</span>
Developmental regulation of thymocyte proliferation in p27 -/- mice
###end title 18
###begin p 19
###xml 319 328 319 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g003">Figure 3A</xref>
###xml 727 736 727 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g003">Figure 3B</xref>
###xml 870 879 870 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g003">Figure 3C</xref>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 618 622 <span type="species:ncbi:10090">mice</span>
###xml 765 769 <span type="species:ncbi:10090">mice</span>
###xml 864 868 <span type="species:ncbi:10090">mice</span>
The large increase in splenic T cells prompted us to examine thymocyte cellularity and proliferation. While we found large variations in thymic cellularity even within the same genotype, on average Bcl-2 expression reduced thymocyte cell number in p27 +/- mice while cell number was increased by Bcl-2 in p27 -/- mice (Figure 3A). We next examined the effect of p27 deficiency on the percentage of proliferating thymocytes (%S/G2/M). For this data, we found an age dependent effect of Bcl-2 on cell proliferation. In 4-6 week old mice, while Bcl-2 decreased the percentage of cycling cells in both p27 +/- and p27 -/- mice, the p27 -/- cohort had significantly higher percentage of cycling cells compared to the p27 +/- group (Figure 3B). However, in 7-12 week old mice, Bcl-2 inhibited thymocyte cell proliferation to the same extent in either p27 +/- or p27 -/- mice (Figure 3C).
###end p 19
###begin title 20
###xml 58 62 <span type="species:ncbi:10090">mice</span>
Thymocyte cellularity and cell cycle in p27 -/- Lck-Bcl-2 mice.
###end title 20
###begin p 21
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 490 494 <span type="species:ncbi:10090">mice</span>
###xml 583 587 <span type="species:ncbi:10090">mice</span>
###xml 653 657 <span type="species:ncbi:10090">mice</span>
###xml 716 720 <span type="species:ncbi:10090">mice</span>
###xml 781 785 <span type="species:ncbi:10090">mice</span>
A) Total thymocyte cellularity from mice of the indicated genotypes (Mean +/- SEM) between 4 and 12 weeks of age is shown. B) DNA content analysis was performed on freshly isolated thymocytes on mice of the indicated genotypes between 4 and 6 weeks of age. The mean and SD of at least 3 mice per group is shown. * P<0.01 versus the control p27 +/-, p27+/- Lck-Bcl-2 and p27 -/-mice using the unpaired Students T test. C) DNA content analysis was performed on freshly isolated thymocytes on mice of the indicated genotypes between 7 and 12 weeks of age. The mean and SD of at least 3 mice per group is shown. # P<0.01 versus both the p27 +/- and p27 -/- mice using the unpaired Students T test. The p27 +/- Lck-Bcl-2 mice were not significantly different than the P27 -/- Lck-Bcl-2 mice in this age group (P = 0.94).
###end p 21
###begin title 22
###xml 40 44 <span type="species:ncbi:10090">mice</span>
Bcl-2 delays cell cycle entry in p27-/- mice
###end title 22
###begin p 23
###xml 92 96 92 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Cheng1">[29]</xref>
###xml 98 102 98 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Vairo2">[30]</xref>
###xml 512 521 512 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g004">Figure 4A</xref>
###xml 784 793 784 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g004">Figure 4B</xref>
###xml 831 832 831 832 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 924 933 924 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g004">Figure 4C</xref>
###xml 173 188 <span type="species:ncbi:10090">transgenic mice</span>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
###xml 506 510 <span type="species:ncbi:10090">mice</span>
P27 has been proposed to be a critical mediator of the anti-proliferative function of Bcl-2 [29], [30]. To examine if p27 is required for delayed proliferation in Lck-Bcl-2 transgenic mice, purified splenic T cells from Lck-Bcl-2 p27-/- and control mice were activated with immobilized anti-CD3 antibody. A time course analysis demonstrated that Bcl-2 significantly delayed entry into the cell cycle (%S/G2/M). Surprisingly, the cell cycle delay by Bcl-2 was nearly equivalent in either p27 -/- or p27 +/- mice (Figure 4A). Examination of cell cycle by propidium iodide (PI) staining in multiple independent experiments showed that the percentage of cells that had entered the cell cycle was markedly reduced by Bcl-2 even in p27 -/- cells. This was true at either 24 or 40-42 hours (Figure 4B). When proliferation was measured by 3H-thymidine uptake, Bcl-2 effectively inhibited proliferation in p27 +/- and p27 -/- cells (Figure 4C).
###end p 23
###begin title 24
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Bcl-2 retains anti-proliferative activity in p27 -/- mice.
###end title 24
###begin p 25
###xml 110 131 110 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 785 786 783 784 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 496 500 <span type="species:ncbi:10090">mice</span>
###xml 671 675 <span type="species:ncbi:10090">mice</span>
Splenic T cells were isolated, purified, and activated with immobilized anti-CD3 antibody as described in the Materials and Methods. A) At the time points indicated, T cells were harvested and analyzed for cell cycle using PI staining. The %S/G2/M at each time point is shown. This experiment is representative of at least three independent experiments. B) Shown is the %S/G2/M (mean+/-SD) cell cycle analysis at 24 and 40-42 hours following activation from multiple independent experiments from mice of the indicated genotypes. The differences between the Lck-Bcl-2 samples (p27 +/- vs p27 -/-) were not significant (NS). * P<0.01 versus the control p27 +/- and p27 -/- mice using the unpaired Students T test. C) Proliferation of T cells of the indicated genotypes was determined by 3H-thymidine uptake. Values represent Mean+/-SD of quintuplet samples. All three groups are significantly different from one another with a P value of <0.01 using the Students T test.
###end p 25
###begin title 26
Delayed CDK2 phosphorylation in Bcl-2 T cells is independent of p27
###end title 26
###begin p 27
###xml 97 101 97 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Greider1">[34]</xref>
###xml 472 476 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Holmes1">[35]</xref>
###xml 684 692 684 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g005">Figure 5</xref>
Previous results suggested that Bcl-2 delayed cell cycle correlates with delayed CDK2 activation [34]. This delay has been attributed at least in part to the elevation of p27 in cells expressing Bcl-2. We therefore examined the effect of Bcl-2 on Thr-160 phosphorylation of CDK2 in cells deficient in p27. Phosphorylation at this site has been tightly correlated with activity and is associated with a conformational change in the protein that can be detected by SDS-PAGE [35]. As expected Bcl-2 significantly delayed Thr-160 phosphorylation in p27 sufficient cells after CD3 activation. Surprisingly, a similar inhibition of CDK2 phosphorylation is detected even in p27 -/- T cells (Figure 5). For both p27 +/- and p27 -/- cells, Thr-160 phosphorylation is largely normalized 42 h after CD3 activation showing the delay is transient. These results demonstrate that the delay in CDK2 phosphorylation by Bcl-2 is independent of p27 in this model.
###end p 27
###begin title 28
Bcl-2 inhibition of Cdk2 phosphorylation is independent of p27.
###end title 28
###begin p 29
###xml 13 17 <span type="species:ncbi:10090">mice</span>
T cells from mice of the indicated genotypes were purified and activated with immobilized anti-CD3 antibody prior to harvesting for immunoblot analysis at the time indicated. Immunoblots for total Cdk2, Phospho Thr-160, and Actin as a loading control are shown.
###end p 29
###begin title 30
###xml 54 69 <span type="species:ncbi:10090">transgenic mice</span>
Cyclin D2 and D3 expression is decreased in Lck-Bcl-2 transgenic mice
###end title 30
###begin p 31
###xml 391 399 391 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g006">Figure 6</xref>
###xml 222 237 <span type="species:ncbi:10090">transgenic mice</span>
The progression from G0 to G1 requires the activation of D cyclins prior to the phosphorylation/activation of CDK2. Since the delay in CDK2 phosphorylation was independent of p27, the levels of D type cyclins in Lck-Bcl-2 transgenic mice prior to and after activation with CD3 were determined. Interestingly, there was no change in cyclin D1 levels in T cells following anti-CD3 activation (Figure 6). However, both Cyclin D2 and D3 are markedly increased 29 h after activation with anti-CD3 in the control cells not expressing Bcl-2. In contrast, T cells expressing Bcl-2 did not show an increase in cyclin D2 and D3 29 h after activation. This was true for both p27 +/- and p27 -/- Bcl-2 expressing cells.
###end p 31
###begin title 32
Bcl-2 delays the upregulation of Cyclins D2 and D3 independent of p27.
###end title 32
###begin p 33
###xml 13 17 <span type="species:ncbi:10090">mice</span>
T cells from mice of the indicated genotypes were purified and activated with immobilized anti-CD3 antibody prior to harvesting for immunoblot analysis at the time indicated. Immunoblots for total Cyclin D1, Cyclin D2, Cyclin D3, and Actin as a loading control are shown.
###end p 33
###begin title 34
Bcl-2 and p27 deficiency cooperate in lymphoma formation
###end title 34
###begin p 35
###xml 72 76 72 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Vairo2">[30]</xref>
###xml 430 434 430 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Linette2">[36]</xref>
###xml 522 526 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Nakayama1">[37]</xref>
###xml 884 892 884 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g007">Figure 7</xref>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 345 360 <span type="species:ncbi:10090">transgenic mice</span>
###xml 491 495 <span type="species:ncbi:10090">mice</span>
###xml 644 648 <span type="species:ncbi:10090">mice</span>
###xml 843 858 <span type="species:ncbi:10090">transgenic mice</span>
Since previous studies implicated p27 in cell cycle regulation by Bcl-2 [30] and our preliminary studies demonstrate dramatic lymphoid hyperplasia and an increase in thymocyte proliferation in young p27 -/- Lck-Bcl-2 mice, lymphoma formation was examined in these animals. Previous studies found that lymphoma formation is observed in Lck-Bcl-2 transgenic mice but significant penetrance is not observed until after 1 year of age [36]. Similarly, lymphoma formation is infrequent in p27 -/- mice in the first year of life [37]. In this study, p27 -/- Lck-Bcl-2 and control groups were monitored weekly for evidence of tumors. P27 -/- Lck-Bcl-2 mice were highly susceptible to thymic lymphomas with complete penetrance by 60 weeks of age. Consistent with previous reports, lymphomas were infrequently detected in p27 +/-, p27 -/-, or Lck-Bcl-2 transgenic mice during this time period (Figure 7).
###end p 35
###begin title 36
Bcl-2 synergizes with p27 deficiency to rapidly promote lymphoma formation.
###end title 36
###begin p 37
###xml 96 117 96 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
###xml 544 548 <span type="species:ncbi:10090">mice</span>
Mice of the indicated genotype were followed for thymic tumor free survival as described in the Materials and Methods. Kaplan-Meier lymphoma free survival analysis of mice of the indicated genotypes is shown. Lymphoma formation in p27 -/- Lck-Bcl-2 mice was significantly (P<0.01) accelerated compared to all three of the control groups (p27 +/-, p27 -/-, and p27 +/- Lck-Bcl-2). The other three groups were not significantly different from one another with regards to survival due to thymic tumors. As previously reported, a subset of p27 -/- mice did succumb to pituitary adenomas but these animals had no evidence of thymic lymphomas and were censored from this analysis of lymphoma formation (data not shown).
###end p 37
###begin title 38
P27 -/- Lck-Bcl-2 thymic lymphomas are lymphoblastic and involve multiple organs
###end title 38
###begin p 39
###xml 340 348 340 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g008">Figure 8</xref>
###xml 475 483 475 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g008">Figure 8</xref>
###xml 597 605 597 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g008">Figure 8</xref>
###xml 584 589 <span type="species:ncbi:9606">human</span>
Necropsies of the p27 -/- Lck-Bcl-2 animals generally showed a massively enlarged thoracic tumor that in all cases appeared to arise within the thymus. Most animals were sacrificed due to respiratory compromise/labored breathing from the tumor. Histological examination of H&E stained tumors showed the tumor contained lymphoblastic cells (Figure 8). Histological examination of the tumors demonstrated locally invasive tumors that frequently involved the kidneys and liver (Figure 8). Immunohistochemical staining showed the tumor cells were Thy1 positive and retained expression of human Bcl-2 (Figure 8). These results confirm that the thoracic tumors are aggressive T cell thymic lymphomas.
###end p 39
###begin title 40
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Tumors from p27 -/- Lck-Bcl-2 mice are aggressive T cell lymphoblastic lymphomas.
###end title 40
###begin p 41
###xml 72 76 <span type="species:ncbi:10090">mice</span>
###xml 399 404 <span type="species:ncbi:9606">human</span>
Histological analysis of the thoracic tumors from the p27 -/- Lck-Bcl-2 mice is shown as indicated. H&E staining shows a characteristic lymphoblastic lymphoma (Top left) that were frequently locally invasive (Heart) and involved distant organs such as the kidney and liver. Immunohistochemistry staining of the liver confirms the tumors are of T cell origin (Thy1 positive) and retain expression of human BCL-2.
###end p 41
###begin title 42
P27 deficiency fails to promote lymphoma development in Lck-Bax38/1mice
###end title 42
###begin p 43
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Luke1">[18]</xref>
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Knudson2">[38]</xref>
###xml 461 465 461 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-vandeWetering1">[19]</xref>
###xml 576 585 576 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g009">Figure 9A</xref>
###xml 730 739 730 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001911-g009">Figure 9B</xref>
###xml 316 331 <span type="species:ncbi:10090">transgenic mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 506 510 <span type="species:ncbi:10090">mice</span>
###xml 559 574 <span type="species:ncbi:10090">transgenic mice</span>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
###xml 713 728 <span type="species:ncbi:10090">transgenic mice</span>
In contrast to Bcl-2, Bax has been shown to have pro-apoptotic function. Despite this pro-apoptotic activity, expression of Bax in thymocytes accelerates T cell lymphoma development [18], [38]. Given the cooperation between p27 deficiency and Bcl-2, the effect of p27 deficiency on lymphoma formation in Lck-Bax38/1 transgenic mice was determined. In young mice, increased Bax expression results in dramatic thymic lymphopenia concordant with previous findings [19] which was modestly increased in p27 -/- mice. This was true for both control and Lck-Bax38/1 transgenic mice (Figure 9A). However, in contrast to Lck-Bcl-2 mice, p27 deficiency had no affect on the development of lymphoma formation in Lck-Bax38/1 transgenic mice (Figure 9B).
###end p 43
###begin title 44
###xml 69 73 <span type="species:ncbi:10090">mice</span>
p27 deficiency does not accelerate lymphoma formation in Lck-Bax38/1 mice.
###end title 44
###begin p 45
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 470 474 <span type="species:ncbi:10090">mice</span>
A) Thymic cellularity from young mice of the indicated genotypes is shown. Data represent the Mean+/-SD of at least four animals from each group. In all cases, Lck-Bax38/1 mice had significantly reduced cellularity compared to the three transgene negative control groups shown on the left. *P<0.05 vs the respective p27 +/+ and p27 +/- controls. B) Kaplan-Meier analysis for lymphoma free survival comparing p27 -/- Lck-Bax38/1 (diamond) and p27 +/- Lck-Bax38/1 (Delta) mice is shown.
###end p 45
###begin title 46
Discussion
###end title 46
###begin p 47
###xml 348 352 348 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Janumyan1">[28]</xref>
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Vairo2">[30]</xref>
###xml 464 468 464 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Vairo2">[30]</xref>
###xml 25 31 <span type="species:ncbi:9606">humans</span>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
Numerous studies in both humans and mice have shown paradoxical effects of Bcl-2 on tumor formation. Several studies have attributed these paradoxical effects to the anti-proliferative activity of Bcl-2. Bcl-2 mediated inhibition of proliferation has been tightly correlated with the anti-apoptotic function of Bcl-2 and to increased levels of p27 [28]-[30]. In fact, in one model Bcl-2 expression was unable to inhibit T cell proliferation in p27 deficient cells [30]. These studies prompted us to determine if p27 is an important tumor suppressor downstream of Bcl-2. In this study, we hypothesized that p27 deficiency would cooperate with Bcl-2 in tumor formation. Consistent with this hypothesis, lymphoma formation was dramatically accelerated by combining the loss of p27 with the expression of Bcl-2.
###end p 47
###begin p 48
###xml 42 46 42 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Nakayama2">[39]</xref>
###xml 56 60 56 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Roussel1">[40]</xref>
###xml 143 147 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Roussel1">[40]</xref>
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Sharpless1">[41]</xref>
###xml 446 450 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Brugarolas1">[42]</xref>
###xml 452 456 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Deng1">[43]</xref>
###xml 585 589 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Nakayama1">[37]</xref>
###xml 591 595 591 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Kiyokawa1">[44]</xref>
###xml 936 940 936 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Fero1">[45]</xref>
###xml 941 945 941 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-PhilippStaheli1">[47]</xref>
###xml 1087 1091 1086 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Martins1">[48]</xref>
###xml 1093 1097 1092 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Geisen1">[49]</xref>
###xml 394 398 <span type="species:ncbi:10090">mice</span>
###xml 483 487 <span type="species:ncbi:10090">mice</span>
###xml 616 620 <span type="species:ncbi:10090">mice</span>
###xml 718 722 <span type="species:ncbi:10090">mice</span>
###xml 1017 1021 <span type="species:ncbi:10090">mice</span>
###xml 1061 1064 <span type="species:ncbi:8790">Emu</span>
###xml 1069 1073 <span type="species:ncbi:10090">mice</span>
###xml 1240 1244 <span type="species:ncbi:10090">mice</span>
CKI's inhibitors include both the Cip/Kip [39] and INK4 [40] families. For the INK family, p16 has been clearly shown to be a tumor suppressor [40], [41]. For the members of the Cip/Kip family, their roles as bonafide tumor suppressors are not as well established. P21 was one of the first known targets of p53 and as such was proposed to act as a tumor suppressor. Surprisingly, p21 deficient mice failed to develop tumors at a significant rate [42], [43]. Similarly, p27 deficient mice demonstrate multiple defects in growth control but are not particularly prone to tumor formation [37], [44]. Though some of the mice develop pituitary adenomas, spontaneous aggressive malignancies are rare. However, p27 deficient mice are prone to develop aggressive malignancies when combined with a deletion in tumor suppressor genes such as p53 or INK4a/ARF, or when challenged with mutagens such as X-irradiation or N-ethyl-N-nitrosourea (ENU) [45]-[47]. Moreover, lymphoma formation was rapidly accelerated in p27 deficient mice expressing the dominant oncogenes myc (Emu-myc mice) or cyclin E [48], [49]. Together, these findings demonstrate that the absence of p27 by itself is not predominantly oncogenic; however, p27 deficiency can sensitize mice to other oncogenic insults. The study described here extends these studies and demonstrates that p27 is an important tumor suppressor in the context of Bcl-2 expression.
###end p 48
###begin p 49
###xml 631 635 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Schmitt1">[50]</xref>
###xml 637 641 637 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Gurova1">[51]</xref>
###xml 764 768 764 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Luke1">[18]</xref>
###xml 770 774 770 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-vandeWetering1">[19]</xref>
###xml 1285 1289 1285 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Callagy1">[52]</xref>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 298 302 <span type="species:ncbi:10090">mice</span>
###xml 759 763 <span type="species:ncbi:10090">mice</span>
###xml 1025 1029 <span type="species:ncbi:10090">mice</span>
###xml 1068 1073 <span type="species:ncbi:9606">human</span>
In contrast to the result with Bcl-2, the absence of p27 had no impact on lymphoma formation in mice expressing pro-apoptotic Bax. The data clearly show that complete elimination of p27 had no additive effect on tumor formation and only a modest increase in thymic cellularity in young Lck-Bax38/1 mice. These results support the idea that Bax and Bcl-2 mediate tumor formation by distinct pathways, consistent with their opposing function in regulating cell death. Previous studies have shown that Bcl-2 expression maintains genome stability by abrogating the selective pressure(s) needed to lose p53 in experimental tumor models [50], [51]. However, the Bcl-2 family has paradoxical effects on lymphoma formation and chromosomal instability even in p53 -/- mice [18], [19]. These data demonstrate the paradoxical effects of the Bcl-2 family are in some cases independent of p53 and suggest that the effects of Bcl-2 on tumor formation are not singularly dependent on whether the tumors retain or lose p53. These studies in mice are consistent with a recent study of human breast cancer that showed Bcl-2 expression provides a favorable prognosis independent of several risk factors including the Nottingham Prognostic Index and was a more important prognostic factor than p53 status [52].
###end p 49
###begin p 50
###xml 204 205 204 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 247 251 247 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Vairo2">[30]</xref>
###xml 409 410 409 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 580 585 <span type="species:ncbi:10090">mouse</span>
###xml 668 671 <span type="species:ncbi:8790">Emu</span>
###xml 1004 1008 <span type="species:ncbi:10090">mice</span>
###xml 1029 1033 <span type="species:ncbi:10090">mice</span>
###xml 1037 1041 <span type="species:ncbi:10090">mice</span>
###xml 1098 1102 <span type="species:ncbi:10090">mice</span>
###xml 1151 1155 <span type="species:ncbi:10090">mice</span>
The ability of Bcl-2 to retain its cell cycle inhibitory affect on splenic T cells in the absence of p27 was surprising. A previous report had found that Bcl-2 expression in T cells was unable to inhibit 3H-thymidine uptake in p27 deficient cells [30]. This is in contrast to our findings that Bcl-2 effectively inhibits splenic T cell proliferation as measured by cell cycle analysis of PI stained nuclei or 3H-thymidine uptake in p27 deficient cells. While the explanation for this discrepancy is not clear, one possibility may be that the studies employed different transgenic mouse models. Our study utilized the Lck promoter and the study by Vairo et. al. used a Emu-promoter. It is possible that Bcl-2 expression is higher in the Lck model and the singularly important role of p27 is apparent at lower levels of Bcl-2 expression. In any case, we did find a role for p27 in a developmentally dependent manner. We demonstrated that Bcl-2 more effectively inhibited thymocyte proliferation in p27 +/- mice compared to p27 -/- mice in mice between 4 and 6 weeks of age. These differences between mice with and without p27 were not observed in older mice between 7 and 12 weeks of age. These results suggest that the effects of p27 in this model are age dependent and as the animal ages, the extent of T cell hyperplasia becomes more pronounced. The cells are then reduced in size and p27 independent pathways are able to inhibit T cell proliferation. Our studies suggest that delayed up regulation of Cyclin D2 and Cyclin D3 may mediate the p27 independent cell cycle inhibition by Bcl-2.
###end p 50
###begin p 51
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Cheng1">[29]</xref>
###xml 401 408 401 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 596 600 596 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Rathmell1">[53]</xref>
###xml 148 153 <span type="species:ncbi:10090">mouse</span>
###xml 1048 1052 <span type="species:ncbi:10090">mice</span>
The results described confirm and extend our previous report in which inhibition of T cell proliferation by Bcl-2 was dependent upon the age of the mouse, the extent of T cell hyperplasia and the reduction in T cell size [29]. In our working model, we propose that a decrease in a survival/proliferative signal results in a reduction in T cell size and a delay in cell proliferation. For T cells, the in vivo survival/proliferative signal may involve interactions between the T Cell Receptor (TCR) on the T cells with the Major Histocompatibility Complex (MHC) on antigen presenting cells (APCs) [53]. When Bcl-2 is expressed, the selective reduction of T cell death leads to an increase in the ratio of T Cells to APC's in an age dependent manner. This altered ratio decreases the TCR/MHC interactions, results in the reduction in T cell size and delayed proliferation. Our studies show the primary function of p27 is to regulate the extent of T cell hyperplasia while inhibition of T cell size and cell cycle remains intact even in p27 deficient mice.
###end p 51
###begin p 52
###xml 385 389 385 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Vairo2">[30]</xref>
###xml 607 611 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Alao1">[54]</xref>
###xml 627 631 627 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Engedal1">[55]</xref>
The studies here demonstrate that Bcl-2 significantly delays the increase in expression of both Cyclin D2 and Cyclin D3 in a manner that is independent of p27. This delay correlates with a delay in Cdk2 phosphorylation which has been tightly linked to exit from G1. This data provide yet another mechanism by which Bcl-2 may inhibit cell cycle in addition to the p27 and p130 pathways [30]. The studies here have not addressed the mechanism by which Bcl-2 delays the up-regulation of Cyclin D2 and D3. However, other studies show the levels of the Cyclin D family are controlled by either protein stability [54] or mRNA levels [55]. In summary, these data demonstrate a complex relationship between the Bcl-2 family, cellular proliferation, and oncogenesis and demonstrate that p27 up-regulation is not singularly important in the Bcl-2 mediated proliferative delay observed in T cells. Nonetheless, the results indicate that p27 plays a critical role in tissue homeostasis and in tumor development in the context of Bcl-2 expression.
###end p 52
###begin title 53
Materials and Methods
###end title 53
###begin title 54
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice
###end title 54
###begin p 55
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Knudson1">[33]</xref>
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Knudson2">[38]</xref>
###xml 189 193 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Luke1">[18]</xref>
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Fero1">[45]</xref>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
Lck-Bcl-2 and Lck-Bax38/1 were previously described and were genotyped by PCR [33], [38]. Lck-Bax38/1 are mice that harbor two independent transgenic Bax constructs as previously described [18]. P27 deficient mice [45] were obtained from Jackson Labs (Stock #003122) and were genotyped by PCR as recommended by Jackson Labs.
###end p 55
###begin title 56
Tumor development studies
###end title 56
###begin p 57
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 119 123 <span type="species:ncbi:10090">Mice</span>
###xml 332 336 <span type="species:ncbi:10090">mice</span>
###xml 429 433 <span type="species:ncbi:10090">mice</span>
###xml 454 458 <span type="species:ncbi:10090">mice</span>
###xml 1122 1126 <span type="species:ncbi:10090">mice</span>
All mice were maintained in the animal facility at the University of Iowa under an approved protocol (ACURF #0310191). Mice of the appropriate genotypes were mated to obtain animals for the tumor development studies. Littermate controls or controls from the same mating pairs were used for all these studies. When possible, p27 -/- mice were used for matings to provide the highest percentage of transgene positive-p27 deficient mice. Therefore, p27 +/- mice were used as controls. Upon entry into the tumor development study, animals were examined weekly for signs of illness or malignancy. Sick animals were monitored more frequently and euthanized when necessary to prevent unnecessary suffering. Control animals were monitored for at least one year and then killed for necropsy. These animals did not show any evidence of lymphoma and were all censored from the analysis of tumor free survival. When possible, necropsies were performed on dead animals to determine if the animals had gross evidence of lymphoma. Tumors were then confirmed by fixation with formalin and histological examination after H&E staining. All mice were maintained in the animal facility at the University of Iowa (Iowa City, IA). Statistical analysis was performed with the StatView Program (SAS Institute Inc.) using Kaplan-Meier cumulative survival and the Logrank (Mantel-Cox) test to determine if differences in survival were significant between each of the indicated groups.
###end p 57
###begin title 58
Cell preparation, analysis and CD3 activation
###end title 58
###begin p 59
###xml 215 216 215 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 489 493 489 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Emerson1">[56]</xref>
###xml 689 693 689 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Knudson1">[33]</xref>
###xml 397 402 <span type="species:ncbi:120290">Guava</span>
###xml 419 424 <span type="species:ncbi:120290">Guava</span>
###xml 849 853 <span type="species:ncbi:10090">mice</span>
Single cell suspensions from either the spleen or thymus were prepared by dispersing the organ between two glass slides in PBS. Red blood cells were removed by 5-minute incubation in hypotonic lysis buffer (0.83% NH4Cl, 10 mM Tris/pH 7.2). The viable cell counts for both the thymus and the spleen were determined using a hemocytometer and trypan blue exclusion or using Viacount reagent with the Guava flow cytometer (Guava Technologies, Hayward, California, USA) as previously described [56]. Splenic T cells were quantified by staining the cells with anti-CD3 (eBioscience #16-0031) and anti-B220 (eBioscience #12-0452) antibodies and analyzed by flow cytometry as previously described [33]. For cell size determination, the mean fluorescence intensity of the forward scatter parameter (FSC) was determined for the CD3 positive cells. At least 5 mice between 5 and 12 weeks of age was recorded for each of the 4 groups. Differences between groups were determined by the t-Test assuming unequal variance (within Microsoft excel). Total splenic T cells were calculated by multiplying the %CD3-positive by the total number of splenic cells.
###end p 59
###begin p 60
###xml 128 132 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Cheng1">[29]</xref>
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Hadzic1">[57]</xref>
###xml 724 725 724 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 784 788 784 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Cheng1">[29]</xref>
###xml 912 916 912 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Emerson1">[56]</xref>
###xml 1027 1031 1027 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001911-Cheng1">[29]</xref>
###xml 842 847 <span type="species:ncbi:120290">Guava</span>
Splenic T cells were purified using reagents and protocols from Stem Cell Technologies (Product #13051) as previously described [29], [57]. Cell purity was generally greater than 95% based on CD3-positive staining. Purified T cells (0.5 to 1.0 million cells/ml) were seeded onto either 96 well plates (0.2 ml for cell cycle studies) or 6 well plates (5-6 ml for immunoblots) that were pre-coated with saturating amounts of anti-CD3 antibody (145-2C11 eBioscience #16-0031-85). Cells were cultured in RPMI-1640 supplemented with 10% FBS, 0.1 mM 2-mercaptoethanol, 200 mM glutamine, and penicillin/streptomycin. At various times following activation, cells were harvested and prepared for analysis. Cell cycle PI staining and 3H-thymidine analysis was performed as previously described [29]. Cell viability was performed in duplicate using the Guava Flow cytometer and the ViaCount reagent as previously described [56]. For immunoblot analysis, cells were harvested, lysates prepared, and blots performed as previously described [29]. Antibodies used for immunoblot analysis were purchased as follows: pCDK2-Thr-160 (Cell Signaling Technology #2561S); CDK2 (Santa Cruz #SC-163); Actin (Sigma #A4700); Cyclin D1 (Sigma #C7464); Cyclin D2 (Sigma #C7339); cyclin D3 (BD Pharminigen #610279).
###end p 60
###begin p 61
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice were generated and maintained at the University of Iowa Transgenic Animal Facility that is supported in part by the Roy J. and Lucille P. Carver College of Medicine. We acknowledge Sean Martin, Matthew Kemp, Agniezka Wydra, and Peter Harris for expert technical assistance and animal husbandry.
###end p 61
###begin title 62
References
###end title 62
###begin article-title 63
Nucleotide sequence of a t(14:18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18.
###end article-title 63
###begin article-title 64
###xml 47 52 <span type="species:ncbi:9606">human</span>
Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18.
###end article-title 64
###begin article-title 65
The t(14:18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining.
###end article-title 65
###begin article-title 66
BCL-2 Family -Regulators of Cell Death.
###end article-title 66
###begin article-title 67
Bcl-2-family proteins and the role of mitochondria in apoptosis.
###end article-title 67
###begin article-title 68
Regulation of mitochondrial membrane premeabilization by BCL-2 family proteins and caspases.
###end article-title 68
###begin article-title 69
The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability.
###end article-title 69
###begin article-title 70
Bcl-2-related proteins and cancer.
###end article-title 70
###begin article-title 71
Bcl-2 is a useful prognostic marker in Dukes' B colon cancer.
###end article-title 71
###begin article-title 72
Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and Bcl-2.
###end article-title 72
###begin article-title 73
Prognostic significance of bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma.
###end article-title 73
###begin article-title 74
###xml 108 115 <span type="species:ncbi:9606">patient</span>
Immunohistochemically detectable bcl-2 expression in colorectal carcinoma-correlation with tumour stage and patient survival.
###end article-title 74
###begin article-title 75
Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer.
###end article-title 75
###begin article-title 76
###xml 110 118 <span type="species:ncbi:9606">patients</span>
The bcl-2 protein-a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.
###end article-title 76
###begin article-title 77
###xml 67 82 <span type="species:ncbi:10090">transgenic mice</span>
Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice.
###end article-title 77
###begin article-title 78
###xml 87 102 <span type="species:ncbi:10090">transgenic mice</span>
Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice.
###end article-title 78
###begin article-title 79
###xml 32 38 <span type="species:ncbi:10090">murine</span>
Targeted expression of bcl-2 to murine basal epidermal keratinocytes results in paradoxical retardation of ultraviolet- and chemical-induced tumorigenesis.
###end article-title 79
###begin article-title 80
###xml 28 43 <span type="species:ncbi:10090">transgenic mice</span>
Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability.
###end article-title 80
###begin article-title 81
###xml 87 92 <span type="species:ncbi:10090">mouse</span>
Chromosomal instability and supernumerary centrosomes represent precursor defects in a mouse model of T-cell lymphoma.
###end article-title 81
###begin article-title 82
###xml 49 55 <span type="species:ncbi:10090">murine</span>
Growth factor starvation of bcl-2 overexpressing murine bone marrow cells induced refractoriness to IL-3 stimulation of proliferation.
###end article-title 82
###begin article-title 83
The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry.
###end article-title 83
###begin article-title 84
Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival.
###end article-title 84
###begin article-title 85
The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry.
###end article-title 85
###begin article-title 86
Expression of a Bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo.
###end article-title 86
###begin article-title 87
bcl-2 transgene expression promotes survival and reduces proliferation of CD3-CD4-CD8- T cell progenitors.
###end article-title 87
###begin article-title 88
Crosstalk between cell death and cell cycle progression: Bcl-2 regulates NFAT-mediated activation.
###end article-title 88
###begin article-title 89
Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease.
###end article-title 89
###begin article-title 90
Bcl-x(L)/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry.
###end article-title 90
###begin article-title 91
Bcl-2 inhibition of T-cell proliferation is related to prolonged T-cell survival.
###end article-title 91
###begin article-title 92
Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation.
###end article-title 92
###begin article-title 93
CDK inhibitors: positive and negative regulators of G1-phase progression.
###end article-title 93
###begin article-title 94
Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes.
###end article-title 94
###begin article-title 95
Bcl-2 and Bax function independently to regulate cell death.
###end article-title 95
###begin article-title 96
BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases.
###end article-title 96
###begin article-title 97
The role of Thr160 phosphorylation of Cdk2 in substrate recognition.
###end article-title 97
###begin article-title 98
###xml 42 57 <span type="species:ncbi:10090">transgenic mice</span>
Peripheral T-cell lymphoma in lckpr-bcl-2 transgenic mice.
###end article-title 98
###begin article-title 99
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking p27(kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.
###end article-title 99
###begin article-title 100
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Bax accelerates tumorigenesis in p53-deficient mice.
###end article-title 100
###begin article-title 101
Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development.
###end article-title 101
###begin article-title 102
The INK4 family of cell cycle inhibitors in cancer.
###end article-title 102
###begin article-title 103
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.
###end article-title 103
###begin article-title 104
Radiation-induced cell cycle arrest compromised by p21 deficiency.
###end article-title 104
###begin article-title 105
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking p21(c/p1/waf1) undergo normal development, but are defective in g1 checkpoint control.
###end article-title 105
###begin article-title 106
###xml 19 23 <span type="species:ncbi:10090">mice</span>
Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1).
###end article-title 106
###begin article-title 107
###xml 4 10 <span type="species:ncbi:10090">murine</span>
The murine gene p27Kip1 is haplo-insufficient for tumour suppression.
###end article-title 107
###begin article-title 108
###xml 96 100 <span type="species:ncbi:10090">mice</span>
Different cooperating effect of p21 or p27 deficiency in combination with INK4a/ARF deletion in mice.
###end article-title 108
###begin article-title 109
###xml 27 31 27 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kip1</sup>
###xml 40 44 40 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cip1</sup>
Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development.
###end article-title 109
###begin article-title 110
###xml 11 15 11 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kip1</sup>
###xml 27 31 27 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cip1</sup>
###xml 78 84 <span type="species:ncbi:10090">murine</span>
Loss of p27Kip1 but not p21Cip1 decreases survival and synergizes with MYC in murine lymphomagenesis.
###end article-title 110
###begin article-title 111
###xml 11 15 11 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kip1</sup>
Loss of p27Kip1 cooperates with cyclin E in T-cell lymphomagenesis.
###end article-title 111
###begin article-title 112
Dissecting p53 tumor suppressor functions in vivo.
###end article-title 112
###begin article-title 113
Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor.
###end article-title 113
###begin article-title 114
Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index.
###end article-title 114
###begin article-title 115
In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability.
###end article-title 115
###begin article-title 116
The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention.
###end article-title 116
###begin article-title 117
###xml 66 71 <span type="species:ncbi:9606">Human</span>
All-trans Retinoic Acid Stimulates IL-2-Mediated Proliferation of Human T Lymphocytes: Early Induction of Cyclin D3.
###end article-title 117
###begin article-title 118
Taurine monochloramine activates a cell death pathway involving Bax and caspase-9.
###end article-title 118
###begin article-title 119
The role of low molecular weight thiols in T lymphocyte proliferation and IL-2 secretion.
###end article-title 119
###begin p 120
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 120
###begin p 121
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: CIvdW was supported in part by a National Research Service Award (NRSA) predoctoral fellowship grant #F31CA103363. This work was supported by NIH grants 1RO1CA104695 and 1RO1CA88967 (C.M.K.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 121

